Equites Radar

HLN · Haleon plc

Drug Manufacturers - Specialty & GenericUnited KingdomAnalyst view: none

$9.78

+3.32% last session

End-of-day data · updated 2026-07-28

Mildly bullish3 bullish · 1 bearish technical signals
To mean target: +19.1%

Market cap

$44B

Enterprise value

$51B

Trailing P/E

20.3

Forward P/E

16.4

Dividend yield

2.0%

Beta

0.24

Avg volume

9M

Employees

25K

2D change

1.64%

5D change

2.37%

10D change

-1.58%

30D change

7.58%

60D change

9.71%

MTD change

5.74%

YTD change

-0.38%

Analyst Outlook

Consensus rating
Recommendation mean (1–5)
Covering analysts5
Mean price target$11.65
Low price target$10.00
Upside to mean target+19.1%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)66.1
50-day MA$9.36
200-day MA$9.68
Price vs 50-day MA+9.7%
Price vs 200-day MA+6.1%
MACD histogram0.01
Volume vs 3-month avg1.7×
52w low $8.6152w high $11.12

Analyst sentiment over time — HLN

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-01-23

Latest call per bank · past 12 months

Barclays

Overweight

$0.00

-100.0% vs price
Upgrade · 2026-01-23

Recent rating actions

DateFirmActionRatingPrice target
2026-01-23BarclaysUpgradeEqual-WeightOverweight$0.00
2025-09-16BarclaysDowngradeOverweightEqual-Weight$0.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 66 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 9.7% above the 50-day MA ($9.36).
  • Price vs 200-day MA: Trading 6.1% above the 200-day MA ($9.68).
  • MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
  • MACD (12,26,9): MACD histogram is positive (+0.01) — short-term momentum is improving.
  • 52-week range: Price sits between the 52-week low ($8.61) and high ($11.12).

HLN Price Chart

Loading chart for HLN

Fundamentals

Revenue (TTM)$11B
EBITDA$3.0B
Free cash flow$1.0B
Operating cash flow$3.0B
Book value / share$4.91
Net debt / EBITDA2.7
WACC6.0%
Revenue growth1.00%
Earnings growth92.00%

About Haleon plc

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

More in Drug Manufacturers - Specialty & Generic

Screen HLN against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.